Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,670.00
Bid: 1,670.50
Ask: 1,671.00
Change: 17.00 (1.03%)
Spread: 0.50 (0.03%)
Open: 1,650.00
High: 1,677.00
Low: 1,646.00
Prev. Close: 1,653.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks Down As Clinton Remarks Hit Pharma Sector

Thu, 25th Aug 2016 11:00

LONDON (Alliance News) - Pharmaceutical stocks dragged the FTSE 100 lower midday Thursday, after the sector was hit by comments made by presidential nominee Hillary Clinton, who raised concerns about the price increase of an allergy product by US pharmaceutical company Mylan.

The price of the company's EpiPen product has risen by 480% since the company acquired it in 2007, moving from USD100 for a 2-pack in 2007 to its current cost of around USD600.

"That's outrageous - and it's just the latest troubling example of a company taking advantage of its consumers," said Clinton in a statement published on her Facebook profile. "It's wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them."

Mike van Dulken, head of research at Accendo Markets, said Clinton's comments will cause concern for healthcare groups and their investors everywhere.

"As always, the industry remains between a rock and a hard place, treading the fine line between balancing the costs of clinical success (and failure) with the economic laws of supply and demand, all the while trying (often in vain) to satisfy demanding stakeholders without appearing to view the sick as merely a commercial opportunity," van Dulken said.

Hikma Pharmaceuticals was down 3.6%, Shire down 4.4%, AstraZeneca down 1.8%, and GlaxoSmithKline down 0.7%.

The FTSE 100 was down 0.3%, or 18.32 points, at 6,817.46. The FTSE 250 was down 0.8% at 17,869.99 and the AIM All-Share was down 0.5% at 788.35.

In Europe, the French CAC 40 was down 0.7% and the German DAX 30 was down 0.9%

Futures indicated a lower open for Wall Street, with the DJIA, S&P 500, and Nasdaq 100 all pointed down 0.1%.

Elsewhere on the London market, CRH was the best performer in the blue-chip index, up 3.4%. The Irish building materials company said its profit came in six times higher than a year earlier in its first half, reflecting continued positive momentum in the Americas and the inclusion of acquisitions made in the second half of 2015.

CRH said trading conditions in the first half in Europe reflected the modest impact of early-stage economic recovery.

In the Americas, the company said it expects the positive momentum seen in construction markets during the first half of the year to continue into the second, while in Asia the positive demand backdrop experienced in the Philippines looks set to continue for the rest of the year.

ITV said it has withdrawn its proposal to acquire Entertainment One, after the television and film producer rejected the bid earlier this month.

ITV made an offer for Entertainment One at 236.00 pence per share, valuing it at around GBP1.03 billion, in early August, but this bid was rebuffed by Entertainment One's board as it said it "fundamentally undervalues" the business.

ITV said Thursday that it has a "clear view of the value" of Entertainment One, and it "appears this value is different to the level at which the board of eOne would currently engage in a more formal process."

The broadcaster said it has a "clear strategy to build a stronger, more diversified international business and will continue its disciplined approach to evaluating its healthy pipeline of potential investment opportunities."

ITV traded up 1.5%, while Entertainment One was the biggest faller in the FTSE 250 index, down 12% to 220.21p.

Infrastructure investor John Laing Group said its net asset value rose in the first half of 2016 and maintained its full year guidance for investment commitments.

The company's net asset value per share also rose to 263.00 pence at the end of its first half from 242.00p at the end of December and 224.00p a year earlier.

"These results demonstrate that our business model is delivering consistent results, and has the ability to cope with today's changing macro-economic environment, including the impact of Brexit," said Chief Executive Olivier Brousse.

The stock was one of the best FTSE 250 performers, up 5.6%.

Playtech was up 4.3% after the gaming technology company reported growth in revenue in the first half and declared a special dividend, but said its profit dipped due to higher finance costs hit by the depreciation of sterling.

Playtech added it was "cognisant" of the need for an efficient balance sheet and said its currently high cash balance is complemented by cash from operations.

It added it is able to return cash to shareholders without impact in its outlook on making more acquisitions. As such, it will pay an interim dividend of 11.0 euro cents per share, up 15% from the previous year, and declared a special dividend of a further 46.0 cents per share.

Still ahead in the economic calendar, US initial and continuing jobless claims are at 1330 BST, alongside durable goods data. Markit's US services and composite PMI readings are at 1445 BST.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.